NanoViricides, Inc. (NASDAQ:NNVC)

BRIEF

published on 10/15/2025 at 14:50, 6 months 17 days ago

NanoViricides Pursues Dual-Track Clinical Strategy for NV-387

Respiratory Viruses Broad-spectrum Antiviral Phase II Trials NV-387 Development MPox Trial
PRESS RELEASE

published on 10/15/2025 at 14:45, 6 months 17 days ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
NanoViricides, Inc. reveals dual-track clinical development strategy for NV-387 targeting respiratory viral infections including Influenzas, Coronaviruses, RSV. Analyst report details trials and future prospects

Respiratory Viral Infections NV-387 NanoViricides Inc. Analyst Report Clinical Development Strategy
BRIEF

published on 09/30/2025 at 14:50, 7 months 1 day ago

NanoViricides' NV-387 Advances in Clinical Trials

NanoViricides NV-387 Clinical Trials Antiviral Therapy Funding Challenges
PRESS RELEASE

published on 09/30/2025 at 14:45, 7 months 1 day ago

NanoViricides, Inc. Has Filed its Annual Report
NanoViricides reports progress on antiviral NV-387 in Phase II clinical trials with potential to revolutionize treatment for respiratory viral infections. Annual report highlights achievements and funding status

NanoViricides NV-387 Clinical Trials Respiratory Infections Antiviral
BRIEF

published on 09/11/2025 at 14:35, 7 months 20 days ago

NanoViricides to Present at LSX World Congress in Boston

NanoViricides NV-387 Clinical Trials Antiviral Drug LSX Congress
PRESS RELEASE

published on 09/11/2025 at 14:30, 7 months 20 days ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. announces participation in LSX World Congress 2025 to present revolutionary broad-spectrum antiviral drug NV-387 and potential impact on viral infections

NanoViricides NV-387 Antiviral Drug Viral Infections LSX World Congress
BRIEF

published on 09/09/2025 at 14:35, 7 months 22 days ago

NanoViricides to Showcase Revolutionary Antiviral Drug at LSX Congress

NanoViricides NV-387 Antiviral Drugs Clinical Trial LSX Congress
PRESS RELEASE

published on 09/09/2025 at 14:30, 7 months 22 days ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. to showcase revolutionary antiviral drug NV-387 at LSX World Congress 2025 in Boston. Update on drug pipeline and platform technologies by Dr. Diwan

NanoViricides NV-387 Antiviral Drug LSX World Congress Dr. Diwan
BRIEF

published on 08/18/2025 at 14:35, 8 months 14 days ago

NanoViricides Reports Promising Antiviral Drug NV-387 in Clinical Trials

NV-387 Clinical Trials Antiviral Drug Inflammation Anti-cancer
PRESS RELEASE

published on 08/18/2025 at 14:30, 8 months 14 days ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
NanoViricides, Inc. reports NV-387 antiviral drug could reduce metastatic cancer resurgence caused by viral infections. NV-387 completed Phase I trial, advancing to Phase II

NV-387 NanoViricides Inc. Antiviral Drug Viral Infections Metastatic Cancer

Published on 05/01/2026 at 15:35, 1 hour 55 minutes ago

LNG Energy Group Announces Partial Revocation of Cease Trade Order and Proposed Private Placement
Published on 05/01/2026 at 14:00, 3 hours 30 minutes ago

CCL Industries Closing of ALT Technologies Acquisition
Published on 05/01/2026 at 14:00, 3 hours 30 minutes ago

Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions
Published on 05/01/2026 at 13:01, 4 hours 29 minutes ago

BeMetals Announces Resumption of Trading on TSX Venture Exchange and Effective Date of Share Consolidation
Published on 05/01/2026 at 13:00, 4 hours 30 minutes ago

Abasca Resources to Participate in Core Days 2026 and Closes $2.5 Million Private Placement

View all ACCESSWIRE

Published on 05/01/2026 at 17:21, 9 minutes ago

Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 05/01/2026 at 15:59, 1 hour 31 minutes ago

Shares Admitted to Trading and Total Voting Rights
Published on 05/01/2026 at 15:37, 1 hour 53 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 05/01/2026 at 15:36, 1 hour 54 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 05/01/2026 at 15:35, 1 hour 55 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc

View all EQS

Published on 04/30/2026 at 20:00, 21 hours 29 minutes ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 22 hours 14 minutes ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 22 hours 30 minutes ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 23 hours 20 minutes ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 23 hours 30 minutes ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News